Comparative Pharmacology
Head-to-head clinical analysis: LEVEMIR FLEXPEN versus LEVEMIR INNOLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVEMIR FLEXPEN versus LEVEMIR INNOLET.
LEVEMIR FLEXPEN vs LEVEMIR INNOLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Long-acting insulin analog that activates insulin receptors, promoting cellular glucose uptake and inhibiting hepatic gluconeogenesis.
Insulin detemir is a long-acting recombinant human insulin analog. It binds to insulin receptors, activating tyrosine kinase signaling, which promotes cellular glucose uptake, inhibits hepatic gluconeogenesis, and suppresses lipolysis and proteolysis.
Subcutaneous injection. Initial dose: 0.2-0.5 units/kg/day once daily or divided into two doses. Titrate by 2-10 units once or twice weekly based on glycemic control. Maximum dose not defined.
0.2 units/kg subcutaneously once daily in the evening or twice daily (morning and evening) when used as basal insulin; titrate to target fasting glucose. For insulin-naive patients with type 2 diabetes, start at 10 units once daily in the evening. Dose adjustment of 1-4 units per day based on blood glucose monitoring.
None Documented
None Documented
Terminal elimination half-life approximately 5-7 hours in children (<6 years: 3-4 hours); provides flat, prolonged pharmacokinetic profile over 24 hours with no pronounced peak.
Terminal elimination half-life is 13–14 hours after subcutaneous administration, providing a flat, protracted pharmacokinetic profile suitable for once-daily dosing.
Renal (30-40% unchanged), remainder hepatically metabolized and excreted in bile/feces; negligible fecal elimination of parent drug.
Hepatic metabolism (deamidation at B30 and deacetylation at B29) and subsequent renal excretion; ~30% of dose excreted unchanged in urine.
Category C
Category C
Antidiabetic (Long-Acting Insulin)
Antidiabetic (Long-Acting Insulin)